ANDROGENS AND THE RISK OF CARDIOVASCULAR DISEASE Summary
Conventional wisdom, arising from over 50 years of research, holds that estrogens reduce the risk of diseases such as myocardial infarction and stroke whereas androgens increase this risk. At a time when the claimed arterial benefit of estrogen is being strongly challenged by the recent failure of several placebocontrolled studies of vascular endpoints, it is timely to reconsider the likely cardiovascular impact of androgen therapy in aging men. The negative image of androgens results in part from inappropriate extrapolation from studies of athletes using combinations of high doses of illicit steroids without medical supervision. Androgenic changes in the plasma lipoprotein profile involve a mixture of changes thought to be good and changes thought to be bad. Likewise, the ability of androgens to increase plaque size seen in fat-fed monkeys is accompanied by potentiallybeneficial changes in lumen volume (due to arterial remodelling) and vascular reactivity. Testosterone dilates coronary arteries and in short-term studies has proved useful in treating arterial disease. Men with high plasma testosterone concentrations are at low, not high, risk of arterial disease. Such contradictions need to be resolved in placebo-controlled clinical trials, most realistically using newly-developed techniques for non-invasive monitoring of plaque structure and composition. 
Résumé

INTRODUCTION
The issue of androgen therapy in aging men has for some time been clouded by disagreement over the existence of a hypogonadal state analogous to postmenopausal hypo-estrogenemia. Recent years have seen the realisation that increased lifespan carries with it the prospect of many decades of old age for men, accompanied not only by physical burdens -such as osteoporosis and heart disease -, but also more general issues of cognitive decline and loss of well-being. In many societies aging women now take estrogens and other steroid hormones in order to improve their physical and mental well-being. Androgen
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therapy in the aging male may well be of similar benefit. If, as is likely, such therapies move out of the private clinic and into the public domain then the risk/ benefit ratio needs to be clarified.
The major causes of mortality and morbidity in men living in industrialised societies are myocardial infarction and stroke. Steroid hormones have been linked to the pathogenesis of both conditions. In the context of women's health these are major areas of controversy: older oral contraceptive formulations were thought to increase the risk of arterial disease, whereas postmenopausal estrogen therapy is claimed to reduce this risk. In neither case is there a consensus of opinion and indeed recent placebo-controlled trials of estrogen replacement therapy show a pattern of increased risk in the early years of treatment. That such controversies persist despite tens of millions of women being treated with such steroids, often for decades, is a cautionary tale for those wishing to evaluate the cardiovascular effects of androgen therapy in the aging male.
THE PERCEPTION OF ANDRO-GENS AS ATHEROGENIC STEROIDS
The gender difference in arterial disease seen before the age of 50 years Premenopausal women are less likely to suffer from arterial disease than are age-matched men, but this could equally be due to protective effects of estrogen, or to adverse effects of other aspects of masculinity, such as personality type or lifestyle. Overall the gender difference in arterial disease dictates that the effect of androgen therapies be taken seriously, but the idea that such therapies must increase the risk of arterial disease is unsustainable.
Reports of arterial disease in athletes abusing anabolic androgenic steroids
The media have a fixation that anabolic androgenic steroids (AAS) cause heart disease. The death (age 38 y) of the USA sprinter Florence Griffith-Joyner, whose 100 m and 200 m sprint world records still stand after 12 years, continues to be promoted as a cautionary tale of AASinduced 'heart disease' even though her autopsy clearly showed suffocation due to epilepsy, with no arterial pathology.
In the USA the prevalence of AAS abuse ranges from 38-55 % of bodybuilders through 15-20 % of college athletes and, most alarmingly, perhaps 10 % of male high school students. However, sports science researchers have been unable to find the predicted epidemic of arterial disease. Even if such a problem could be identified, the relevance of such findings to the much lower doses of steroids used under medical supervision in the aging male is questionable.
Changes in risk factors for atherosclerosis
Androgens can increase plasma concentrations of low density lipoproteins (LDL) and decrease those of high density lipoproteins (HDL). Neither effect is considered desirable, although only minor changes are seen with current therapies. In the case of HDL, research in this laboratory and others suggests that steroids that reduce HDL concentrations do not necessarily impair HDL functions such as promotion of cholesterol efflux from cells. Indeed the recent identification of HDL receptors such as scavenger receptor B1 (SR-B1) raises the possibility that reducing HDL concentrations by some mechanisms might even be beneficial. It is noteworthy that one of the most widely recommended strategies to prevent arterial disease -a lowfat diet -reduces HDL concentrations. A further complication is that population studies consistently show that it is the man with low plasma testosterone concentrations who has the low HDL concentrations.
High-dose androgens given to female-to-male transsexuals impair the flow-mediated response of brachial arteries (proposed as a surrogate for arterial disease), perhaps involving an effect on endothelin- 
